The number of patients treated for severe withdrawal linked to medetomidine—a powerful veterinary sedative increasingly found in fentanyl—quadrupled in recent years, according to a new analysis by researchers at the Perelman School of Medicine, including Margaret Lowenstein. The study, published in JAMA Internal Medicine, confirms observations by medical professionals who have treated the drug’s particularly intense withdrawal symptoms with specialized care, including infused medications and intensive care unit (ICU) stays.
Severe withdrawal cases point to growing medetomidine use
